Amgen Completes Onyx Pharmaceuticals Tender Offer

Thousand Oaks-based Amgen reported this morning that it has completed its tender offer for Onyx Pharmaceuticals, and now expects its acquisition to complete today. Amgen said the deal is worth $9.7 billion net of estimated cash at Onyx. Amgen is paying $125 per share in cash for publicly held Onyx Pharmaceuticals, a developer of biopharmaceuticals for treating cancer. The deal had originally been announced in August.